BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240226
DTEND;VALUE=DATE:20240229
DTSTAMP:20260516T003938
CREATED:20240213T102528Z
LAST-MODIFIED:20240213T102742Z
UID:38686-1708905600-1709164799@www.pharmajournalist.com
SUMMARY:3rd Next-Generation Conjugates Summit
DESCRIPTION:From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology\, to Nurix and Seagen collaborating on a targeted protein degradation conjugate\, there is now a staggering amount of investment and collaboration in the novel conjugates space. \nAs highlighted above\, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma\, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation\, and others continue to innovate in conjugate design\, it is an exciting time for the next-generation conjugates field. \n \nCovering case-study led presentations on novel design concepts\, key translational and clinical development challenges\, and addressing challenging CMC roadblocks\, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads\, with conjugate modality types including antibody-oligonucleotide conjugates\, fragment-drug conjugates\, Targeted Radiopharmaceutical Conjugates\, small molecule-drug conjugates\, bispecific-drug conjugates and more! \nThis is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together\, so make sure to join likeminded conjugate developers to learn\, collaborate and innovate and expand on the potential of conjugate drugs. \nLearn more here: https://ter.li/q5wf9x
URL:http://www.pharmajournalist.com/event/3rd-next-generation-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260516T003938
CREATED:20231011T093613Z
LAST-MODIFIED:20240119T123110Z
UID:37931-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit Europe
DESCRIPTION:Cell therapy continues to transform the oncology field\, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space. \nProviding your team with exclusive access to cutting-edge advances across pre-clinical platforms\, clinical advances\, and streamlined manufacturing\, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.   \n300+ industry experts will brainstorm enhancing target discovery\, optimizing durability of response and identifying biomarkers to support recruitment\, automating production\, and accelerating analytical processes to reduce operational costs and turnaround times.   \nWith a new Biopharma & Investors Evening\, a new C-Level Think Tank\, new speakers and data from Mnemo Therpaeutics\, Cellectis\, Bambino Gesu Hospital and more\, can your team afford to miss out? \nTo know more visit: https://ter.li/6vgioi
URL:http://www.pharmajournalist.com/event/7th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260516T003938
CREATED:20240111T102635Z
LAST-MODIFIED:20240111T102635Z
UID:38483-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:6th Bacteriophage Therapy Summit
DESCRIPTION:The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck\, Pfizer\, SNIPR Biome\, Locus Biosciences\, Phiogen\, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes. \nTake advantage of this unique opportunity to be a part of the dialogue\, meet phage leaders\, large pharma\, and venture capitalists to gain practical takeaways\, and demonstrate the clinical utility of your bacteriophage to form meaningful partnerships. \nJoin us for 3 days of unmissable content\, and accelerate your bacteriophage research into clinical\, meaningful and commercially viable therapies. \nCheck out the full event guide now: https://ter.li/jig8n0
URL:http://www.pharmajournalist.com/event/6th-bacteriophage-therapy-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR